Skip to content
ApprovedFDA approved

HGH

Lab-made growth hormone: a prescription medicine for hormone deficiency that athletes also use off-label to build muscle; banned in sport.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

HGH vial

DETAILED OVERVIEW

What is HGH?

HGH is recombinant human growth hormone: a lab-made version of the hormone that the pituitary gland produces. As a prescription medicine it is approved to treat growth hormone deficiency, Turner syndrome, short stature of unknown cause and wasting linked to AIDS. Athletes also use it off-label for building muscle, recovery and fat loss; in competitive sport it is banned year-round.

Much of its effect is carried by IGF-1, a growth factor made in the liver. Prolonged use can cause acromegaly (enlargement of the hands, feet and jaw), thickening of the heart muscle and insulin resistance. Fluid retention, joint pain and carpal tunnel syndrome, which causes numbness in the hand, are common. It is contraindicated in active cancer and diabetes and should be avoided in pregnancy.

Mechanism

GH receptor agonist, IGF-1 elevator

Half-life

~3 hours (subcutaneous)

Onset

4-8 weeks (IGF-1 peak)

Legal status

USA: FDA Rx. HU/EU: Rx. WADA: banned.

Data console

Lab data

Androgenic:Anabolic-
AR bindingN/A
Active half-life~3 h (subcutaneous)
Detection window~24 h direct rhGH test; biomarker test (IGF-1 + P-III-NP) more sensitive with 7-14 day window.
AromatizationNot applicable – 191-amino-acid peptide hormone (somatotropin), NOT a steroid; no CYP19 interaction
HepatotoxicityLow – no direct hepatotoxicity; IGF-1 elevation indirectly drives T2DM/insulin resistance risk (Mauras 2005)

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Insulin resistance and elevated fasting glucose: GH antagonises insulin and raises hepatic gluconeogenesis/glycogenolysis, pushing toward type 2 diabetes over time (rising HbA1c).
  • Fluid retention and peripheral oedema: sodium and water retention, early and very common, especially above 4 IU/day (puffy face, ankle swelling).
  • Carpal tunnel syndrome and paraesthesia: fluid-related nerve compression causes numbness, tingling and hand pain; usually reversible on dose reduction.
  • Acromegalic changes with chronic/high-dose use: enlargement of hands, feet and jaw, coarsening facial features, organomegaly and arthralgia.
  • Cardiac hypertrophy and cardiomegaly: long-term concentric left-ventricular hypertrophy and impaired contractile function, with the raised cardiovascular mortality seen in acromegaly.
  • Thyroid shift: GH increases T4-to-reverse-T3 conversion and lowers active T3, potentially causing subclinical hypothyroidism (fatigue); rT3/fT3/fT4 monitoring is warranted.
  • Arthralgia, myalgia and joint stiffness: common complaints, partly from fluid retention and partly from tissue growth.
  • Theoretical tumour/growth-promoting risk: chronically high IGF-1 is mitogenic and may accelerate growth of an existing malignancy, hence contraindicated in active cancer.

Contraindications · 7

  • Active malignancy or history of cancer: absolute contraindication due to the mitogenic effect of raised IGF-1.
  • Diabetes, prediabetes or insulin resistance: GH is diabetogenic, worsening glycaemic control and potentially aggravating retinopathy.
  • Acute critical illness (major surgery, multiple trauma, acute respiratory failure): high-dose somatropin increased mortality in ICU trials, contraindicated.
  • Active proliferative or severe diabetic retinopathy: GH/IGF-1 signalling can drive progression.
  • Overt heart failure, uncontrolled hypertension or pre-existing left-ventricular hypertrophy: fluid retention and myocardial growth can precipitate decompensation.
  • Pregnancy and breastfeeding: avoided due to hormonal effects and glucose-metabolism disturbance; safety not established.
  • Non-therapeutic (performance) use: the above risks are unmanageable without medical supervision; WADA-prohibited (category S2).

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about HGH?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.